Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2023 Nov 10;25(Suppl 5):v118. doi: 10.1093/neuonc/noad179.0447

EPID-15. SEX-SPECIFIC DIFFERENCES IN GLIOBLASTOMA IN THE RESPOND CONSORTIUM

Sree Gongala 1, Jose Garcia 2, Nisha Korakavi 3, Nirav Patil 4, Hamed Akbari 5, Charit Tippareddy 6, Andrew Sloan 7, Jill Barnholtz-Sloan 8, Spyridon Bakas 9, Anahita Fathi Kazerooni 10, Chiharu Sako 11, Ujjwal Baid 12, Steven Brem 13, Robert A Lustig 14, Jaume Capellades 15, MacLean Nasrallah 16, Donald M O'Rourke 17, Pamela LaMontagne 18, Daniel S Marcus 19, Carmen Balana 20, Josep Puig 21, Kristin Waite 22, Rivka Colen 23, Yoon Seong Choi 24, Seung-Koo Lee 25, Adam P Dicker 26, Adam E Flanders 27, Wenyin Shi 28, Brent Griffith 29, Laila M Poisson 30, Lisa R Rogers 31, Thomas C Booth 32, Rajan Jain 33, Arnab Chakravarti 34, Joshua Palmer 35, Suyash Mohan 36, Pallavi Tiwari 37, Mariam Aboian 38, Sung Soo Ahn 39, Christos Davatzikos 40, Chaitra Badve 41
PMCID: PMC10639366

Abstract

AIM

The goal of this study was to understand sex-specific differences in the molecular, clinical and radiological tumor parameters and survival outcomes of Glioblastoma (GBM) patients within the international GBM dataset, known as the ReSPOND (Radiomic Signatures for PrecisiON Diagnostics) consortium.

METHODS

Sex-based differences were retrospectively studied in 1922 GBM patients from the ReSPOND consortium which includes information from over 14 institutions across 3 continents. The parameters include age, Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status, isocitrate dehydrogenase 1 (IDH1) mutation status, Karnofsky performance status (KPS), extent of resection (EOR), tumor epicenter, volumes, laterality and spatial extent. Non-parametric tests, log-rank test and cox-proportional hazard analysis were performed to understand sex-based differences in tumor parameters, survival rates and hazard ratios. Spatial atlases were generated to understand radiological parameters such as tumor spatial extent.

RESULTS

GBM in was diagnosed at a median age of 62.6 years in females compared to 61 years in males (p = 0.001). Additionally, 44% females compared to 37% males (p = 0.04) had methylated MGMT and 79% females compared to 73% males (p = 0.004) had IDH1 wildtype. The tumor volumes were smaller in females (necrotic core, edema, and enhancing tumor) compared to males. Females exhibited a higher prevalence of right hemisphere (39.6%) and right temporal lobe tumors (19.7%), while males showed a higher prevalence of left hemisphere (40.3%) left temporal lobe tumors (23.7%). No significant sex-based differences in OS and PFS was observed in overall sample, although longer PFS was observed in elderly (above 60 years) female patients.

CONCLUSION

This is a first international large cohort study looking at sex-based differences in GBM patients using the ReSPOND consortium data. Several sex-specific differences in the distribution of various tumor phenotypes were noted, however sex was not a contributing factor in OS and PFS.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES